About CV TherapeuticsCV Therapeutics, Palo Alto, CA, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular disease focused.
Participant received the MERLIN TIMI – 36 study current standard therapy, with approximately 96 % of patients who received aspirin, approximately 89 % on beta blockers and approximately 82 % on statins. Approximately 59 % of patients received coronary angiography during their initial hospitalization.
In accordance with a Special Protocol Assessment agreement between the U.S. Food and Drug Administration and CV Therapeutics, the Company believes that the data from the MERLIN TIMI – 36 study could to expand the existing Ranexa indication to assist first line angina. In September 2007, the Company has an sNDA to the FDA seeking a new indication for first line angina and a significant reduction in cautionary language.At the conference.quences. PACs presentations, AustraliaThe problem dry eyes is widely used in Australian, it often remain undiagnosed or inadequately treated.
‘There are a lot on causes for dry eyes by Ageing, disease, Surgery and medication adverse reactions. ‘Interventions range from underlying cause as well as the preventive therapies teardrop preservatives , elongation spare (drops of to medical and surgical treatments.. We talk all of these options and how they compare their course in the therapy of, so that pharmacists can use the dry eye patient lead optimum management of their condition Moses will well a lecture on produced complication biphosphonate. Therapyis ophthalmia that can cause uveitis, scleritis and pink eye.
This condition is subject to a special presentation at Pharmacies Australia Congress in Sydney 15 to 18 Oct.